Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adrenosem (Carbazochrome) in Primary Glaucoma and Diabetic Retinopathy

Adrenosem (Carbazochrome) in Primary Glaucoma and Diabetic Retinopathy Abstract Adrenochrome is one of the principal oxidation products of epinephrine and has no significant pressor action. It has been studied in Europe since 1937 and in America since 1951 for its action in control of bleeding from capillaries and venules. Its role seems independent of the chemistry of coagulation, the vitamin K-prothrombin mechanism, and the function of heparin or the usual anticoagulants. It is alleged to reduce capillary permeability and to increase capillary resistance,* a statement echoing data in regard to rutin several years ago. Both natural and synthetic adrenochrome are markedly unstable and insoluble. Evolution of the adrenochrome monosemicarbazone sodium salicylate complex has overcome these chemical difficulties. This product is synthetically prepared in America under the trade name Adrenosem and the generic name of carbazochrome. PREVIOUS REPORT In an uncontrolled, preliminary report of 69 private patients with bleeding problems, Sherber4 found gratifying clinical courses following carbazochrome administration in References 1. References 1 to 3. 2. Supplied by Dr. John Q. Griffith Jr., 2518 W. Harold St., Philadelphia 32. 3. Supplied by Mr. P. E. Carman, Research Department, the S. E. Massengill Company, Bristol, Tenn. 4. Parrot, J. L.: Diminution of Capillary Permeability by Adrenochrome , Compt. rend. Soc. biol. 143:819-822, 1949. 5. Digonnet, L.; Cahn, J.; Dabrasquet, M., and Pierre, R.: Hyaluronidase Inhibitors , Thérapie 7: 254-262, 1952. 6. Sabotka, H., and Adelman, N.: Shortening of Bleeding Time by a Water-Soluble Adrenochrome Derivative , Proc. Soc. Exper. Biol. & Med. 75: 789-791, 1950. 7. Sherber, D. A.: The Control of Bleeding , Am. J. Surg. 86:331-335, 1953. 8. Keeney, A. H., and Leopold, I. H.: Evaluation of Capillary Mechanisms in Primary Glaucoma , A. M. A. Arch. Ophth. 47:720-727, 1952. 9. Wagener, H. P.: Retinopathy in Diabetes Mellitus , Proc. Am. Diabetes A. 5:201-216, 1945. 10. McMaster, P. D.: Changes in Cutaneous Lymphatics in Human Beings , J. Exper. Med. 65: 347-372, 1937. 11. Griffith, J. Q., and Lindauer, M. A.: Medical Treatment of Hypertension , Clinics 5:82-95, 1946. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png A.M.A. Archives of Ophthalmology American Medical Association

Adrenosem (Carbazochrome) in Primary Glaucoma and Diabetic Retinopathy

Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/adrenosem-carbazochrome-in-primary-glaucoma-and-diabetic-retinopathy-dgumbAjkFl

References (10)

Publisher
American Medical Association
Copyright
Copyright © 1955 American Medical Association. All Rights Reserved.
ISSN
0096-6339
DOI
10.1001/archopht.1955.00930020671006
Publisher site
See Article on Publisher Site

Abstract

Abstract Adrenochrome is one of the principal oxidation products of epinephrine and has no significant pressor action. It has been studied in Europe since 1937 and in America since 1951 for its action in control of bleeding from capillaries and venules. Its role seems independent of the chemistry of coagulation, the vitamin K-prothrombin mechanism, and the function of heparin or the usual anticoagulants. It is alleged to reduce capillary permeability and to increase capillary resistance,* a statement echoing data in regard to rutin several years ago. Both natural and synthetic adrenochrome are markedly unstable and insoluble. Evolution of the adrenochrome monosemicarbazone sodium salicylate complex has overcome these chemical difficulties. This product is synthetically prepared in America under the trade name Adrenosem and the generic name of carbazochrome. PREVIOUS REPORT In an uncontrolled, preliminary report of 69 private patients with bleeding problems, Sherber4 found gratifying clinical courses following carbazochrome administration in References 1. References 1 to 3. 2. Supplied by Dr. John Q. Griffith Jr., 2518 W. Harold St., Philadelphia 32. 3. Supplied by Mr. P. E. Carman, Research Department, the S. E. Massengill Company, Bristol, Tenn. 4. Parrot, J. L.: Diminution of Capillary Permeability by Adrenochrome , Compt. rend. Soc. biol. 143:819-822, 1949. 5. Digonnet, L.; Cahn, J.; Dabrasquet, M., and Pierre, R.: Hyaluronidase Inhibitors , Thérapie 7: 254-262, 1952. 6. Sabotka, H., and Adelman, N.: Shortening of Bleeding Time by a Water-Soluble Adrenochrome Derivative , Proc. Soc. Exper. Biol. & Med. 75: 789-791, 1950. 7. Sherber, D. A.: The Control of Bleeding , Am. J. Surg. 86:331-335, 1953. 8. Keeney, A. H., and Leopold, I. H.: Evaluation of Capillary Mechanisms in Primary Glaucoma , A. M. A. Arch. Ophth. 47:720-727, 1952. 9. Wagener, H. P.: Retinopathy in Diabetes Mellitus , Proc. Am. Diabetes A. 5:201-216, 1945. 10. McMaster, P. D.: Changes in Cutaneous Lymphatics in Human Beings , J. Exper. Med. 65: 347-372, 1937. 11. Griffith, J. Q., and Lindauer, M. A.: Medical Treatment of Hypertension , Clinics 5:82-95, 1946.

Journal

A.M.A. Archives of Ophthalmology – American Medical Association

Published: Nov 1, 1955

There are no references for this article.